Proteomic Analysis of Laser Microdissected Ovarian Cancer Tissue with SELDI-TOF MS

  • Isabelle CadronEmail author
  • Toon Van Gorp
  • Philippe Moerman
  • Etienne Waelkens
  • Ignace Vergote
Part of the Methods in Molecular Biology book series (MIMB, volume 755)


The evolution of ovarian cancer will highly depend on platinum sensitivity or resistance. In an attempt to better understand this mechanism of resistance, we combined laser microdissection (LMD) of ovarian tumor cells with mass spectrometric techniques. To obtain disease-specific markers we isolated ovarian tumor cells with LMD without contamination of surrounding cells. Proteins were extracted by chemical lysis and subsequent peptide and protein information was gathered using surface-enhanced laser desorption/ionization-time of flight mass spectrometry.

Key words

Ovarian cancer SELDI-TOF MS Platinum resistance Laser microdissection Biomarkers 


  1. 1.
    Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL and Creasman WT et al. (2006) Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynaecological Cancer. Int J Gynaecol Obstet 95 (suppl. 1), S161–192.Google Scholar
  2. 2.
    Martin LP, Hamilton TC, Schilder RJ. (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14,1291–1295.CrossRefGoogle Scholar
  3. 3.
    Cadron I, Van Gorp T, Timmerman D, Amant F, Waelkens E, Vergote I. (2009) Application of proteomics in ovarian cancer: which sample should be used? Gynecol Oncol 115,497–503.CrossRefGoogle Scholar
  4. 4.
    Yan XD, Pan LY, Yuan Y, Lang JH, Mao N. (2007) Identification of platinum resistant associated proteins through proteomic analysis of human ovarian cancer cells and their platinum resistant sub lines. J Proteome Res 6,772–780.CrossRefGoogle Scholar
  5. 5.
    Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, et al. (2006) Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5,433–443.Google Scholar
  6. 6.
    Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, et al. (2006) Serine proteaseHtrA1 modulates chemotherapy induced cytotoxicity. J Clin Invest 116,1994–2004.CrossRefGoogle Scholar
  7. 7.
    Le Moguen K, Lincet H, Deslandes E, Hubert-Roux M, Lange C, Poulain L, et al. (2006) Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Proteomics 6,5183–5192.CrossRefGoogle Scholar
  8. 8.
    Song J, Shih IeM, Salani R, Chan DW, Zhang Z. (2007) Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 13, 6842–6849.CrossRefGoogle Scholar
  9. 9.
    Cadron I, Van Gorp T, Amant F, Vergote I, Moerman Ph, Waelkens E, Daemen A, Van de Plas R, De Moor B, Zeillinger R. (2009) The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res. 29, 1039–1045.Google Scholar
  10. 10.
    Schutze K, Clement-Sengewald A, Catch and move-cut or fuse. Nature 1994; 368:667–669.CrossRefGoogle Scholar
  11. 11.
    Schultze K, Lahr G, Burgemeister R. (2000) The force of focused light in different areas of cell and molecular biology. J Mol Med 78, B21.Google Scholar
  12. 12.
    Melle C, Ernst G,Schimmel B, Bleul A, Thieme H, Kaufmann R, Mothes H, Settmacher U, Claussen U, Halbhuber KJ, Von Eggeling F. (2005) Discovery and identification of alfa defnsins as low abundant tumor derived serum markers in colorectal cancer. Gastroenterology 129, 66–73.CrossRefGoogle Scholar
  13. 13.
    Diaz JL, Cazares LH, Corica A, Semmes OJ. (2004) Selective capture of prostatic basal cells and secretory epitheial cells for proteomic and genomic analysis. Urologic Oncology 329–336.Google Scholar
  14. 14.
    Kwapiszewska G, Meyer M, Bogumil R, Bohle RM, Seeger W, Weissmann N, Fink L. (2004) Identification of proteins in laser microdissected small cell numbers by SELDI-TOF and Tandem MS, BMC Biotechnology 4, 30.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Isabelle Cadron
    • 1
    Email author
  • Toon Van Gorp
    • 1
    • 2
  • Philippe Moerman
    • 3
  • Etienne Waelkens
    • 4
  • Ignace Vergote
    • 1
  1. 1.Division of Gynecological Oncology, Department of Obstetrics and GynecologyUniversity Hospitals Leuven, Katholieke Universiteit LeuvenLeuvenBelgium
  2. 2.Division of Gynaecological Oncology, Department of Obstetrics and GynaecologyMUMC+, GROW – School for Oncology and Developmental BiologyMaastrichtThe Netherlands
  3. 3.Department of PathologyUniversity Hospitals Leuven, Katholieke Universiteit LeuvenLeuvenBelgium
  4. 4.Department of Molecular Cell BiologyUniversity Hospitals Leuven, Katholieke Universiteit LeuvenLeuvenBelgium

Personalised recommendations